Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging

Journal of Proteomics

Volumn 74, Issue 7, 2011, Pages 982-992

  Marko Varga, György ^a,b   Fehniger, Thomas E ^a,c   Rezeli, Melinda ^a   Döme, Balázs ^d,e   Laurell, Thomas ^a   Végvári, Ákos ^a  

^a LUND UNIVERSITY   (Sweden)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

Author keywords

Erlotinib; Gefitinib; Lung cancer; MALDI MS imaging

Indexed keywords

ERLOTINIB; GEFITINIB;

ADENOCARCINOMA; ARTICLE; CANCER TISSUE; CHEMICAL LABELING; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; IMAGING; LARGE CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; SAMPLING; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

NICOTIANA TABACUM;

EID: 79957632743     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.03.019     Document Type: Article

References (38)

1. Caprioli R.M., Farmer T.B., Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997, 69:4751-4760.
2. Vickerman J.C., Briggs D. ToF-SIMS: surface analysis by mass spectrometry 2001, Surface Spectra Ltd./IM Publications, Chichester, Manchester.
3. Takats Z., Wiseman J.M., Gologan B., Cooks R.G. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 2004, 306:471-473.
4. McDonnell L.A., Piersma S.R., Altelaar A.F.M., Mize T.H., Luxembourg S.L., Verhaert P., et al. Subcellular imaging mass spectrometry of brain tissue. J Mass Spectrom 2005, 40:160-168.
5. Landgraf R.R., Conaway M.C.P., Garrett T.J., Stacpoole P.W., Yost R.A. Imaging of lipids in spinal cord using intermediate pressure matrix-assisted laser desorption-linear ion trap/orbitrap MS. Anal Chem 2009, 81:8488-8495.
6. Nilsson A., Fehniger T.E., Gustavsson L., Andersson M., Kenne K., Marko-Varga G., et al. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS ONE 2010, 5:e11411.
7. Bunch J., Clench M.R., Richards D.S. Determination of pharmaceutical compounds in skin by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Sp 2004, 18:3051-3060.
8. Troendle F.J., Reddick C.D., Yost R.A. Detection of pharmaceutical compounds in tissue by matrix-assisted laser desorption/ionization and laser desorption/chemical ionization tandem mass spectrometry with a quadrupole ion trap. J Am Soc Mass Spectrom 1999, 10:1315-1321.
9. Reyzer M.L., Hsieh Y.S., Ng K., Korfmacher W.A., Caprioli R.M. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 2003, 38:1081-1092.
10. Rohner T.C., Staab D., Stoeckli M. MALDI mass spectrometric imaging of biological tissue sections. Mech Ageing Dev 2005, 126:177-185.
11. Hsieh Y., Chen J., Korfmacher W.A. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J Pharmacol Toxicol Meth 2007, 55:193-200.
12. Reyzer M.L., Chaurand P., Angel P.M., Caprioli R.M. Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectometry. Meth Mol Biol 2010, 656:285-301.
13. Benabdellah F., Touboul D., Brunelle A., Laprevote O. In situ primary metabolites localization on a rat brain section by chemical mass spectrometry imaging. Anal Chem 2009, 81:5557-5560.
14. Bouslimani A., Bec N., Glueckmann M., Hirtz C., Larroque C. Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney. Rapid Commun Mass Sp 2010, 24:415-421.
15. Cristoni S., Brioschi M., Rizzi A., Sironi L., Gelosa P., Tremoli E., et al. Analysis of rosuvatatin by imaging mass spectrometry. Rapid Commun Mass Sp 2006, 20:3483-3487.
16. Goodwin R.J., MacIntyre L., Watson D.G., Scullion S.P., Pitt A.R. A solvent-free matrix application method for matrix-assisted laser desorption/ionization imaging of small molecules. Rapid Commun Mass Sp 2010, 24:1682-1686.
17. Hsieh Y., Casale R., Fukuda E., Chen J.W., Knemeyer I., Wingate J., et al. Matrix-assisted laser desorption/ionization imaging mass spectrometry for direct measurement of clozapine in rat brain tissue. Rapid Commun Mass Sp 2006, 20:965-972.
18. Solon E.G., Schweitzer A., Stoeckli M., Prideaux B. Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development. Aaap J 2010, 12:11-26.
19. Sugiura Y., Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 2010, 5:31-43.
20. Signor L., Varesio E., Staack R.F., Starke V., Richter W.F., Hopfgartner G. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. J Mass Spectrom 2007, 42:900-909.
21. Stoeckli M., Staab D., Schweitzer A. Compound and metabolite distribution measured by MALDI mass spectrometric imaging in whole-body tissue sections. Int J Mass Spectrom 2007, 260:195-202.
22. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
23. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
24. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
25. Okano T., Kondo T., Fujii K., Nishimura T., Takano T., Ohe Y., et al. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 2007, 13:799-805.
26. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer - a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177:1348-1357.
27. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
28. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.
29. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20.
30. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
31. Marko-Varga G., Ogiwara A., Nishimura T., Kawamura T., Fujii K., Kawakami T., et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res 2007, 6:2925-2935.
32. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004, 350:1713-1721.
33. Ogiwara A., Kawakami T., Nagasaka K., Tanaka N., Wada K., Otsuji M., et al. Keys to success for large-scale proteomics analysis conducted with a clinical study 2009, 252-254. Ook-Press Ltd, Veszprém, Hungary. G. Marko-Varga, T. Laurell (Eds.).
34. Laurell T., Wallman L., Nilsson J. Design and development of a silicon microfabricated flow-through dispenser for on-line picolitre sample handling. J Micromech Microeng 1999, 9:369-376.
35. Végvári Á., Fehniger T.E., Gustavsson L., Nilsson A., Andrén P.E., Kenne K., et al. Essential tactics of tissue preparation and matrix nano-spotting for successful compound imaging mass spectrometry. J Proteomics 2010, 73:1270-1278.
36. Vorm O., Roepstorff P., Mann M. Improved resolution and very high-sensitivity in MALDI TOF of matrix surfaces made by fast evaporation. Anal Chem 1994, 66:3281-3287.
37. Önnerfjord P., Ekström S., Bergquist J., Nilsson J., Laurell T., Marko-Varga G. Homogeneous sample preparation for automated high throughput analysis with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Rapid Commun Mass Sp 1999, 13:315-322.
38. Herbst R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003, 30:34-46.